Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Atlas Venture
AddedFeb 11, 2024
UpdatedJul 2, 2026
Atlas Venture

Atlas Venture

Operating

Atlas Ventures LLC: A US-based venture capital firm investing in early-stage tech and life science startups.

Location
Cambridge, MA, US
Founded
1980
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Triveni Bio
Triveni Bio
Series C

Total Raised

$272M

Rounds

3

Series B$115MOctober 2024
Series A$92MOctober 2023
Accent Therapeutics
Accent Therapeutics

Total Raised

$178M

Rounds

3

Series C$75MJanuary 2024
Comanche Biopharma
Comanche Biopharma

Total Raised

$111.1M

Rounds

2

Series B$75MJanuary 2024
Remix Therapeutics
Remix Therapeutics

Total Raised

$211M

Rounds

4

Series Unknown$60MJanuary 2024
Series B$70MMay 2022
Aiolos Bio
Aiolos Bio
Acquired

Total Raised

$245M

Rounds

1

Series A$245MOctober 2023
Nvelop Therapeutics
Nvelop Therapeutics

Total Raised

$100M

Rounds

1

Seed$100MSeptember 2023
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Private Equity$210MSeptember 2023
Late Stage Private$125MSeptember 2022
Series Unknown$105MJuly 2021
K36 Therapeutics
K36 Therapeutics

Total Raised

$100M

Rounds

2

Series B$70MJune 2023
Series A$30MDecember 2021
Right-Hand Cybersecurity
Right-Hand Cybersecurity

Total Raised

$6M

Rounds

2

Series A$5MMarch 2023
Chroma Medicine
Chroma Medicine

Total Raised

$260M

Rounds

3

Series B$135MMarch 2023
Sionna Therapeutics
Sionna Therapeutics

Total Raised

$110M

Rounds

1

Series B$110MApril 2022
Be Biopharma
Be Biopharma

Total Raised

$182M

Rounds

2

Series B$130MApril 2022
Triana Biomedicines
Triana Biomedicines

Total Raised

$160.8M

Rounds

4

Series A$110MApril 2022
Arkuda Therapeutics
Arkuda Therapeutics

Total Raised

$108M

Rounds

3

Series B$64MFebruary 2022
Korro Bio
Korro Bio
Public

Total Raised

$207.5M

Rounds

4

Series B$116MJanuary 2022
Curie Therapeutics
Curie Therapeutics
Acquired

Total Raised

$75M

Rounds

1

Series A$75MDecember 2021
HotSpot Therapeutics
HotSpot Therapeutics

Total Raised

$210M

Rounds

4

Series C$100MNovember 2021
Matchpoint Therapeutics
Matchpoint Therapeutics

Total Raised

$100M

Rounds

2

Seed$30MNovember 2021
Rectify Pharmaceuticals
Rectify Pharmaceuticals

Total Raised

$100M

Rounds

1

Series A$100MOctober 2021
Obsidian Therapeutics
Obsidian Therapeutics

Total Raised

$164.5M

Rounds

2

Series B$115MSeptember 2021